Organization
Tulane University, New Orleans, LA
4 abstracts
Abstract
Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials.Org: Artera, Vancouver, BC, Canada, Department of Pathology, University of California San Francisco, San Francisco, CA, Tulane University, New Orleans, LA, University of California, San Francisco, San Francisco, CA, Case Western Reserve University, Cleveland, OH,
Abstract
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).Org: Prostate Cancer Foundation, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Mayo Clinic,
Abstract
A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.Org: Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Virginia Oncology Associates, U.S. Oncology Research, Barbara Ann Karmanos Cancer Institute,
Abstract
Associations between androgen-directed treatments and AR mutational landscapes in the circulating tumor DNA of a real-world metastatic prostate cancer cohort.Org: Tulane University, New Orleans, LA, Tempus Labs, Inc., Tulane Cancer Center,